170 related articles for article (PubMed ID: 37952541)
1. Optimising follow-up strategy based on cytology and human papillomavirus after fertility-sparing surgery for early stage cervical cancer: a nationwide, population-based, retrospective cohort study.
Schuurman TN; Schaafsma M; To KH; Verhoef VMJ; Sikorska K; Siebers AG; Wenzel HHB; Bleeker MCG; Roes EM; Zweemer RP; de Vos van Steenwijk PJ; Yigit R; Beltman JJ; Zusterzeel PLM; Lok CAR; Bekkers RLM; Mom CH; van Trommel NE
Lancet Oncol; 2023 Dec; 24(12):1349-1358. PubMed ID: 37952541
[TBL] [Abstract][Full Text] [Related]
2. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
3. Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation.
Verguts J; Bronselaer B; Donders G; Arbyn M; Van Eldere J; Drijkoningen M; Poppe W
BJOG; 2006 Nov; 113(11):1303-7. PubMed ID: 16978225
[TBL] [Abstract][Full Text] [Related]
4. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
Gilham C; Sargent A; Kitchener HC; Peto J
Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
[TBL] [Abstract][Full Text] [Related]
5. Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.
Ogilvie GS; van Niekerk D; Krajden M; Smith LW; Cook D; Gondara L; Ceballos K; Quinlan D; Lee M; Martin RE; Gentile L; Peacock S; Stuart GCE; Franco EL; Coldman AJ
JAMA; 2018 Jul; 320(1):43-52. PubMed ID: 29971397
[TBL] [Abstract][Full Text] [Related]
6. The 5-year risk of recurrence of grade 2/3 cervical intraepithelial neoplasia after treatment in a population screening programme by human papillomavirus status: A cohort study in central Italy.
Visioli CB; Iossa A; Gorini G; Mantellini P; Lelli L; Auzzi N; Pierro CD; Carozzi FM; Zappa M
J Med Screen; 2023 Dec; 30(4):191-200. PubMed ID: 37229655
[TBL] [Abstract][Full Text] [Related]
7. Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis.
Arbyn M; Redman CWE; Verdoodt F; Kyrgiou M; Tzafetas M; Ghaem-Maghami S; Petry KU; Leeson S; Bergeron C; Nieminen P; Gondry J; Reich O; Moss EL
Lancet Oncol; 2017 Dec; 18(12):1665-1679. PubMed ID: 29126708
[TBL] [Abstract][Full Text] [Related]
8. Follow-up strategies after treatment (large loop excision of the transformation zone (LLETZ)) for cervical intraepithelial neoplasia (CIN): Impact of human papillomavirus (HPV) test.
van der Heijden E; Lopes AD; Bryant A; Bekkers R; Galaal K
Cochrane Database Syst Rev; 2015 Jan; 1(1):CD010757. PubMed ID: 25562623
[TBL] [Abstract][Full Text] [Related]
9. Role of human papillomavirus testing and cytology in follow-up after conization.
Gosvig CF; Huusom LD; Deltour I; Andersen KK; Duun-Henriksen AK; Madsen EM; Petersen LK; Elving L; Schouenbourg L; Iftner A; Svare E; Iftner T; Kjaer SK
Acta Obstet Gynecol Scand; 2015 Apr; 94(4):405-11. PubMed ID: 25645089
[TBL] [Abstract][Full Text] [Related]
10. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease.
Kreimer AR; Guido RS; Solomon D; Schiffman M; Wacholder S; Jeronimo J; Wheeler CM; Castle PE
Cancer Epidemiol Biomarkers Prev; 2006 May; 15(5):908-14. PubMed ID: 16702369
[TBL] [Abstract][Full Text] [Related]
12. Type-specific HPV geno-typing improves detection of recurrent high-grade cervical neoplasia after conisation.
Heymans J; Benoy IH; Poppe W; Depuydt CE
Int J Cancer; 2011 Aug; 129(4):903-9. PubMed ID: 21064091
[TBL] [Abstract][Full Text] [Related]
13. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
[TBL] [Abstract][Full Text] [Related]
14. Analysis of Residual/Recurrent Disease and Its Risk Factors after Loop Electrosurgical Excision Procedure for High-Grade Cervical Intraepithelial Neoplasia.
Wu J; Jia Y; Luo M; Duan Z
Gynecol Obstet Invest; 2016; 81(4):296-301. PubMed ID: 26337009
[TBL] [Abstract][Full Text] [Related]
15. Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial.
Elfström KM; Smelov V; Johansson AL; Eklund C; Nauclér P; Arnheim-Dahlström L; Dillner J
BMJ; 2014 Jan; 348():g130. PubMed ID: 24435414
[TBL] [Abstract][Full Text] [Related]
16. Cytology and human papillomavirus testing 6 to 12 months after ASCUS or LSIL cytology in organized screening to predict high-grade cervical neoplasia between screening rounds.
Tropé A; Sjøborg KD; Nygård M; Røysland K; Campbell S; Alfsen GC; Jonassen CM
J Clin Microbiol; 2012 Jun; 50(6):1927-35. PubMed ID: 22518869
[TBL] [Abstract][Full Text] [Related]
17. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial.
Carozzi F; Gillio-Tos A; Confortini M; Del Mistro A; Sani C; De Marco L; Girlando S; Rosso S; Naldoni C; Dalla Palma P; Zorzi M; Giorgi-Rossi P; Segnan N; Cuzick J; Ronco G;
Lancet Oncol; 2013 Feb; 14(2):168-76. PubMed ID: 23261355
[TBL] [Abstract][Full Text] [Related]
18. Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain.
Ibáñez R; Moreno-Crespi J; Sardà M; Autonell J; Fibla M; Gutiérrez C; Lloveras B; Alejo M; Català I; Alameda F; Casas M; Bosch FX; de Sanjosé S
BMC Infect Dis; 2012 Jan; 12():25. PubMed ID: 22280073
[TBL] [Abstract][Full Text] [Related]
19. Risk of cervical precancer among HPV-negative women in the Netherlands and its association with previous HPV and cytology results: A follow-up analysis of a randomized screening study.
Inturrisi F; Rozendaal L; Veldhuijzen NJ; Heideman DAM; Meijer CJLM; Berkhof J
PLoS Med; 2022 Oct; 19(10):e1004115. PubMed ID: 36306283
[TBL] [Abstract][Full Text] [Related]
20. HPV-based strategy in follow-up of patients treated for high-grade cervical intra-epithelial neoplasia: 5-year results in a public health surveillance setting.
Garutti P; Borghi C; Bedoni C; Bonaccorsi G; Greco P; Tognon M; Martini F
Eur J Obstet Gynecol Reprod Biol; 2017 Mar; 210():236-241. PubMed ID: 28068597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]